VA Salt Lake City Health Care System, Salt Lake City, UT
Welcome,         Profile    Billing    Logout  
 50 Trials 
18 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stehlik, Josef
NCT05420012: The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

Completed
4
26
US
Vericiguat, VERQUVO, Placebo, Control group
Josef Stehlik, Merck Sharp & Dohme LLC
Heart Failure, Heart Failure with Reduced Ejection Fraction (HFrEF)
10/24
10/24
NCT03644667: Tocilizumab in Cardiac Transplantation

Active, not recruiting
2
385
US
tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone
National Institute of Allergy and Infectious Diseases (NIAID), PPD
Heart Transplant
04/25
04/25
DETECT, NCT05081739: Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation

Withdrawn
N/A
600
NA
Prospera Transplant Assessment, Endomyocardial biopsy
Natera, Inc.
Heart Transplant Failure and Rejection
01/25
01/26
ACES-EMB, NCT06414603: A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

Recruiting
N/A
250
US
The Prospera™ Test
Natera, Inc.
Heart Transplant Failure and Rejection
12/24
12/25
NCT04707872: Trifecta-Heart cfDNA-MMDx Study

Recruiting
N/A
300
Europe, Canada, US, RoW
MMDx diagnostic test, Prospera, HLA antibody
University of Alberta, Natera, Inc., One Lambda
Heart Transplant Rejection
12/26
07/27
DEFINE-HT, NCT05309382: Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation

Completed
N/A
147
US
Prospera
Natera, Inc.
Heart Transplant
10/24
10/24
Johnson, Jessica
NEPTUNUS-2, NCT05349214 / 2021-005687-22: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Recruiting
3
1683
US
Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management
University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca
Intracranial Arteriosclerosis, Stroke
05/28
05/28
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

Recruiting
1/2
40
US
NRTX-1001, GABA-secreting interneurons, Sham Comparator
Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM)
Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis
05/25
05/26
NCT02844465: Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)

Completed
N/A
167
US
Visualase MRI-Guided Laser Ablation, Visualase System, Visualase procedure, Laser interstitial thermal therapy, Stereotactic laser ablation
MedtronicNeuro
Temporal Lobe Epilepsy
12/23
12/23
Brooke, Benjamin
JETi, NCT04370691: Peripheral Thrombectomy Registry

Active, not recruiting
N/A
260
Europe, Canada, US, RoW
JETi Peripheral Thrombectomy System
Abbott Medical Devices
Peripheral Artery Thrombosis, Peripheral Venous Thrombosis
08/24
08/25
DuVall, Scott L
VALOR-VA, NCT05663957: eVusheld Assessment reaL wORld Effectiveness in the VA Health System

Completed
N/A
5814
US
Evusheld
AstraZeneca, VA Informatics and Computing Infrastructure (VINCI)
SARS-CoV-2, COVID-19
09/23
09/23
RODRIGUEZ, Leonardo
STEAM T-2DM, NCT05887635: Study of Duodenal Mucosal RF Vapor Ablation in Subjects With Type-2 Diabetes Mellitus

Recruiting
N/A
40
RoW
RF Vapor Ablation
Aqua Medical, Inc.
Diabetes Mellitus Type 2
01/26
06/26
STEAM-IE, NCT06655740: Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes

Recruiting
N/A
16
RoW
RF Vapor Ablation
Aqua Medical, Inc.
Diabetes Mellitus, Type 2
03/25
07/25
NCT06724822: RF Vapor Ablation Retreatment of Duodenal Mucosa in Non-responders With Type-2 Diabetes Mellitus

Enrolling by invitation
N/A
12
RoW
RF Vapor Ablation
Aqua Medical, Inc.
Diabetes Mellitus, Type 2
06/25
10/25
Kurdgelashvili, George
RESTORATiVE303, NCT06237452: VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Recruiting
3
852
Europe, Canada, US, RoW
VE303, Placebo
Vedanta Biosciences, Inc.
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
06/27
10/27
Gawron, Lori
NCT04291001: Ovarian Function With ENG Implant and UPA Use

Completed
1
40
US
ENG implant, Nexplanon, oral ulipristal acetate, Ella
University of Utah, Merck Sharp & Dohme LLC
Contraception
10/22
01/24
Johnson, Lillie
NCT05399537: Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT

Recruiting
3
40
US
Prismocitrate 18
Baxter Healthcare Corporation
Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI)
09/25
09/25
White, P Jon
No trials found
Hanson, Heather
No trials found
Harrigan, Natasha
No trials found

Download Options